Please note that the groupings have been reversed as of October 2005 - this is in order to facilitate the formulation of a grading system for extravasation risk - the higher the grouping, the higher the risk of causing severe and serious tissue damage.
| Neutrals: Group 1 |
Inflammitants: Group 2 |
Irritants: Group 3 |
Exfoliants: Group 4 |
Vesicants: Group 5 |
| Asparaginase |
Etoposide Phosphate |
Carboplatin |
Aclarubicin |
Amsacrine |
| Bleomycin |
Fluorouracil |
Etoposide |
Cisplatin |
Carmustine |
| Cladribine |
Methotrexate |
Irinotecan |
Daunorubicin Liposomal |
Dacarbazine |
| Cyclophosphamide |
Raltitrexed |
Teniposide |
Docetaxel |
Dactinomycin |
| Cytarabine |
|
|
Doxorubicin Liposomal |
Daunorubucin |
| Edroclomab |
|
|
Floxuridine |
Doxorubicin |
| Fludarabine |
|
|
Mitozantrone |
Epirubicin |
| Gemcitabine |
|
|
Oxaliplatin |
Idarubicin |
| Ifosfamide |
|
|
Topotecan |
Mitomycin |
| Melphalan |
|
|
|
Mustine |
| Pentostatin |
|
|
|
Paclitaxel |
| Rituximab |
|
|
|
Streptozocin |
| Thiotepa |
|
|
|
Treosulfan |
| Beta-Interferons |
|
|
|
Vinblastine |
| Aldesleukin (IL-2) |
|
|
|
Vincristine |
| Trastuzemab |
|
|
|
Vindesine |
|
|
|
|
|
Vinorelbine |